BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that Executive Chairman, Pravin U.

贝德福德，马萨诸塞州，2024年4月15日（环球通讯社）--眼科治疗公司（纳斯达克股票代码：OCUL）（“眼科”）是一家生物制药公司，致力于通过开发和商业化治疗湿性年龄相关性黄斑变性（湿性AMD），糖尿病视网膜病变和其他眼部疾病和病症的创新疗法来提高人们的视力和生活质量。

Dugel, MD, is assuming the roles of President and Chief Executive Officer (CEO), and that Antony Mattessich is stepping down as President and CEO, effective immediately. In addition to his new responsibilities, Dr. Dugel will continue to serve as a director and as Executive Chairman of Ocular..

医学博士杜格尔（Dugel）将担任总裁兼首席执行官（CEO），安东尼·马泰西（AntonyMattessich）将辞去总裁兼首席执行官一职，立即生效。除了新的职责外，杜格尔博士还将继续担任眼科的董事和执行主席。。

“On behalf of the Board of Directors and employees of Ocular, I want to wholeheartedly express Ocular’s utmost gratitude for Antony's many years of exceptional service and unwavering commitment to the Company. His passion and dedication has guided Ocular for years, enabling the formation of a high-quality organization and the development of our innovative retinal disease pipeline, led by AXPAXLI™,” said Dr.

“我谨代表欧睿的董事会和员工，衷心感谢安东尼多年来为公司提供的卓越服务和坚定不移的承诺。多年来，他的热情和奉献精神一直指引着欧睿，促成了一个高质量组织的形成，并推动了由AXPAXLI™领导的创新性视网膜疾病管道的开发，”Dr。

Dugel. “I believe AXPAXLI™ has the potential to dramatically change the treatment paradigm for retinal disease and look forward to advancing the development of this innovative product candidate in 2024 and beyond.”.

杜格尔。“我相信AXPAXLI™有可能极大地改变视网膜疾病的治疗模式，并期待在2024年及以后推动这一创新产品候选产品的开发。”。

“The journey with Ocular Therapeutix over the last seven-plus years has been the highlight of my career. Working with the team to emerge from the aftermath of the second CRL with DEXTENZA™, through approval and launch, has been amazing. Now, with AXPAXLI enrolling in the Phase 3 program with a Special Protocol Assessment, the Company is set to advance to the next stage,” said Mr.

“在过去七年多的时间里，眼科治疗的旅程一直是我职业生涯中的亮点。通过批准和推出，与团队合作，用DEXTENZA™从第二次CRL的后果中脱颖而出，这是令人惊讶的。现在，随着AXPAXLI通过特别协议评估加入了第三阶段计划，该公司将进入下一阶段，”Mr。

Mattessich. “As Ocular moves forward to transform into a leading retina care company, I am grateful to the employees, advisors, investors and collaborators who have supported the Company’s development and progress. I ‘pass the baton’ to Pravin with enthusiasm and optimism for all that lies ahead. The Company could not be in better hands.”.

马特西。“随着眼保健公司向领先的视网膜护理公司转型，我感谢支持公司发展和进步的员工、顾问、投资者和合作者。我对未来的一切充满热情和乐观，将接力棒“传递给Pravin。公司再好不过了。”。

About Dr. Dugel, Executive Chairman of the Board, Ocular Therapeutix

关于眼科治疗公司董事会执行主席杜格尔博士

Pravin U. Dugel, MD has held previous leadership roles including President of IVERIC Bio, Inc., Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona..

医学博士Pravin U.Dugel曾担任领导职务，包括IVERIC Bio，Inc.总裁、管理合伙人、亚利桑那州视网膜顾问和视网膜研究所；南加州大学凯克医学院南加州大学眼科研究所临床教授；亚利桑那州太阳城光谱眼科研究所创始成员。。

Dr. Dugel has authored more than 200 papers and 35 book chapters and has been invited to give prestigious named lectures at marquis medical meetings and to serve as a visiting professor at major universities worldwide. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials.

杜格尔博士撰写了200多篇论文和35本书的章节，并应邀在马奎斯医学会议上发表著名的命名演讲，并担任世界各大大学的客座教授。他是几家主要医学期刊的编辑委员会成员。Dugel博士是国际公认的主要临床研究人员，并且是100多个多中心临床试验的主要研究者。

His research and educational contributions earned him the prestigious Honor Award, Senior Honor Award and Lifetime Achievement Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the Board of Directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA.

他的研究和教育贡献为他赢得了美国眼科学会（AAO）享有盛誉的荣誉奖、高级荣誉奖和终身成就奖。他被选为美国眼科学会年会视网膜亚专业日董事会主席，是美国最大的视网膜学会、美国视网膜专家学会（ASRS）和欧洲最大的视网膜学会EURETINA的董事会成员。

Additionally, he has been elected to the Retina Society, Macula Society, and the Retina Hall of Fame..

此外，他还被选入视网膜学会、黄斑学会和视网膜名人堂。。

Dr. Dugel has served as the Chair of the Scientific Advisory Board for major companies, including Novartis, Roche, Genentech, Allergan (Abbvie), Oxurion (Thrombogenics), Oculis, and Alcon. He has consulted for over 50 companies and has previously served on the IVERIC Bio and Aerpio Therapeutics Boards of Directors..

杜格尔博士曾担任诺华（Novartis）、罗氏（Roche）、基因泰克（Genentech）、艾尔根（Allergan）（Abbvie）、Oxurion（Thrombogenics）、Oculis和爱尔康（Alcon）等大公司的科学顾问委员会主席。他曾为50多家公司提供咨询服务，并曾担任过艾瑞克生物和阿尔皮奥治疗公司董事会成员。。

Dr. Dugel has been a member of the Board of Directors and Chair of Orbis International’s Medical Advisory Board and Medical Strategy Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery.

杜格尔博士是奥比斯国际医疗咨询委员会和医疗战略委员会的董事会成员和主席。奥比斯国际是一家非营利性组织，专注于发展中国家的眼科培训和教育。杜格尔博士与奥比斯一起前往发展中国家，向当地眼科医生教授手术技术，并提供免费手术。

In Arizona, Dr. Dugel founded an aviation company allowing him to travel to the Navajo, Hopi and Pima Indian Reservations to treat Native American patients suffering from preventable blindness..

在亚利桑那州，杜格尔博士成立了一家航空公司，允许他前往纳瓦霍、霍皮和皮马印第安人保留地治疗患有可预防失明的美洲原住民患者。。

Dr. Dugel was born in Kathmandu, Nepal, grew up in Vienna, Austria and attended Harrow School in London, England. He graduated summa cum laude from Columbia University in New York City and was elected to the Phi Beta Kappa Society. He was also captain of the Columbia Squash team. He then attended the UCLA School of Medicine, completing his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine.

杜格尔博士出生于尼泊尔加德满都，在奥地利维也纳长大，就读于英国伦敦的哈罗学校。他以优异成绩毕业于纽约哥伦比亚大学，并被选入Phi Beta Kappa协会。他也是哥伦比亚壁球队的队长。然后，他进入加州大学洛杉矶分校医学院，完成了在凯克医学院南加州大学眼科研究所的眼科住院治疗。

Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and surgical retina fellowship at the USC Eye Institute, where he received both the Heed Foundation Fellowship award and Ronald G. Michels Foundation Fellowship award..

此后，他在Bascom Palmer眼科研究所完成了医学视网膜奖学金，并在南加州大学眼科研究所完成了视网膜外科奖学金，在那里他获得了Heed基金会奖学金和Ronald G.Michels基金会奖学金。。

AboutOcularTherapeutix,Inc.

关于Therapeutix，股份有限公司。

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye.

Oyer Therapeutix，Inc.是一家生物制药公司，致力于通过开发和商业化针对湿性年龄相关性黄斑变性（湿性AMD），糖尿病视网膜病变和其他眼部疾病和病症的创新疗法来提高人们的视力和生活质量。

AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in the first of two planned pivotal Phase 3 trials for wet AMD, the SOL-1 trial, and a Phase 1 clinical trial for the treatment of non-proliferative diabetic retinopathy.

眼部视网膜疾病候选产品AXPAXLI™（axitinib玻璃体内植入物，也称为OTX-TKI）基于其ELUTYX™专有的生物可吸收水凝胶制剂技术。AXPAXLI目前正在进行湿性AMD的两项计划关键的3期临床试验中的第一项，即SOL-1试验和用于治疗非增殖性糖尿病视网膜病变的1期临床试验。

The clinical portfolio also includes PAXTRAVA™ (travoprost intracameral implant, also known as OTX-TIC), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension..

临床组合还包括PAXTRAVA™（曲伏前列素前房内植入物，也称为OTX-TIC），目前正在进行治疗原发性开角型青光眼或高眼压的2期临床试验。。

Ocular’s expertise in the formulation, development and commercialization of innovative therapies of the eye and the ELUTYX platform supported the development and launch of its first commercial drug product, DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.

眼科在眼部创新疗法和ELUTYX平台的配方，开发和商业化方面的专业知识支持了其首个商业药物产品DEXTENZA®的开发和推出，DEXTENZA®是FDA批准的皮质类固醇，用于治疗眼科手术后的眼部炎症和疼痛以及与过敏性结膜炎相关的眼部瘙痒。

ELUTYX is also the foundation for two other clinical-stage assets, OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, as well as several preclinical programs..

ELUTYX也是另外两个临床阶段资产的基础，用于慢性治疗干眼症的OTX-CSI（环孢素管内插入物）和用于短期治疗干眼症体征和症状的OTX-DED（地塞米松管内插入物），以及几个临床前计划。。

Follow us on our website, LinkedIn or X.

在我们的网站LinkedIn或X上关注我们。

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, and ELUTYX™ and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

DEXTENZA®是Oyel Therapeutix，Inc.的注册商标。AXPAXLI™、PAXTRAVA™、ELUTYX™和Oyel Therapeutix™是Oyel Therapeutix，Inc.的商标。

Investors

投资者

Ocular Therapeutix

眼疗法

Donald Notman

唐纳德·诺特曼

Chief Financial Officer

首席财务官

dnotman@ocutx.com

dnotman@ocutx.com

Joyce Allaire

乔伊斯·阿莱尔

LifeSci Advisors

LifeSci顾问

jallaire@lifesciadvisors.com

jallaire@lifesciadvisors.com